gemcitabine has been researched along with mrk 003 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bapiro, TE; Cook, N; Demuth, T; Frese, KK; Gopinathan, A; Howat, WJ; Jacobetz, MA; Jodrell, DI; Miller, JL; Rao, SS; Tuveson, DA | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Maitra, A; Matsui, W; Mizuma, M; Omura, N; Puig, O; Rajeshkumar, NV; Rasheed, ZA; Yabuuchi, S; Zhang, Q | 1 |
2 other study(ies) available for gemcitabine and mrk 003
| Article | Year |
|---|---|
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Gemcitabine; Humans; Hypoxia; Mice; Mice, Mutant Strains; Necrosis; Pancreatic Neoplasms; Protease Inhibitors; Receptors, Notch; Signal Transduction; Thiadiazoles; Translational Research, Biomedical | 2012 |
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Receptor, Notch1; Thiadiazoles; Transcriptome; Xenograft Model Antitumor Assays | 2012 |